Clinical Trial Update: A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population

View source ↗

Summary

A completed clinical trial assessing the safety of the 23-valent pneumococcal polysaccharide vaccine in the target population. Sponsor: Sinovac Biotech Co., Ltd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infection

Drugs mentioned

• 23-valent pneumococcal polysaccharide vaccine (PPSV23) (Pneumococcal polysaccharide vaccine, 23-valent)

Snippet

Sponsor: Sinovac Biotech Co., Ltd | Conditions: Pneumococcal Infectious Disease | Status: COMPLETED